KRAS and non-small cell lung carcinoma: Finally, a few KRAS inhibitors are in ongoing clinical trials, including adagrasib (formerly MRTX849), due to the discovery of FDA-approved sotorasib, which was the breakthrough advance in developing targeted therapy for patients with non-small cell lung cancer and KRAS mutations [277].